期刊文献+

药源性骨质疏松的发病原因、致病药物及防治 被引量:3

Drug-induced osteoporosis:mechanisms,causative drug,prevention and treatment
原文传递
导出
摘要 骨质疏松是骨强度受到损害而致骨折风险增加的骨骼疾病,可严重降低患者的生活质量与健康状况。导致药源性骨质疏松的常见药物包括口服抗凝药、钙调磷酸酶抑制剂、强效利尿药、质子泵抑制剂、噻唑烷二酮类降糖药、芳香酶抑制剂、蛋白酶抑制剂、糖皮质激素和抗癫痫药等。致病机制为药物通过促进骨吸收、抑制骨形成、抑制骨矿化影响正常骨代谢。骨密度测定可用于诊断药源性骨质疏松。防治药源性骨质疏松的有效措施包括合理用药,定期监测骨密度,缩短用药疗程,给予患者钙剂、维生素D制剂、双膦酸盐类药物、降钙素、选择性雌激素受体调节剂等药物治疗。 Osteoporosis is a skeletal disorder characterized by compromised bone strength that may predispose to an increased risk of fracture,which can seriously decrease the patient' s quality of life and healthy status.The common drugs causing osteoporosis are oral anticoagulants,calcineurin inhibitors,potent diuretics,proton pump inhibitors,thiazolidinediones,aromatase inhibitors,protease inhibitors,glucocorticoids,antiepileptic drugs,etc.The main mechanisms may involve promoting bone resorption,inhibition of bone formation and bone mineralization.Drug-induced osteoporosis is diagnosed by a bone mineral density test.The effective measures for preventing and treating drug-induced osteoporosis include rational drug use,regularly monitoring of bone mineral density,shortening the duration of therapy,and patients should be administered calcium,vitamin D supplementation,bisphosphonate,calcitonin,selective estrogen receptor modulator,and so on.
作者 刘琛 王育琴
出处 《药物不良反应杂志》 2011年第6期367-372,共6页 Adverse Drug Reactions Journal
关键词 骨质疏松 药源性疾病 防治 osteoporosis drug-induced disease prevention and treatment
  • 相关文献

参考文献33

  • 1陆再英,钟南山.内科学[M].7版.北京:人民卫生出版社,2008:717-718.
  • 2原发性骨质疏松症诊治指南(2011年)[J].中华骨质疏松和骨矿盐疾病杂志,2011,4(1):2-17. 被引量:1833
  • 3Kaukinen S, Koobi T, Bi Y, et al. Cardiac output measurement after coronary artery bypass grafting using bolus thermodilution, continuous thermodilution,and whole body impedance cardiography. J Cardiothorac Vasc Anesth ,2003,17 (4): 199-203
  • 4Barin E, Haryadi DG, Schookin SI, et al. Evaluation of a thoracic bioimpedance cardiac output monitor during cardiac catheterization.Crit Care Med,2000,28 ( 3 ) :698-702
  • 5Noble TJ, Morice AH, Channer KS, et al. Monitoring patients with left ventricular failure by electrical impedance tomography. Heart Fail, 1999,1 ( 12 ) :379-384
  • 6Van De Water JM, Miller TW, Vogel RI, et al. Impedance cardiography: the next vital sign technology? Chest, 2003,123 ( 1 ): 2028-2033
  • 7陈芳,尤传一.甲状腺激素与骨质疏松[J].国外医学(内分泌学分册),2000,20(6):297-299. 被引量:16
  • 8Mazziotti G, Canalis E, Giustina A. Drug-induced osteoporosis : mechanisms and clinical implications [ J ]. Am J Med, 2010, 123(10): 877-884.
  • 9Briot K, Roux C. Drug-induced osteoporosis: beyond glucocorticoids [ J ]. Curr Rheumatol Rep, 2008, 10 (2) : 102-109.
  • 10Yang YX, Lewis JD, Epstein S, et al. Long-term proton pump inhibitor therapy and risk of hip fracture [ J ]. JAMA, 2006, 296 (24) :2947-2953.

二级参考文献71

  • 1彭国光,王玉栋,陈光晔,陈伟良.颌骨放射性骨坏死的预防[J].国外医学(口腔医学分册),1993,20(5):280-284. 被引量:3
  • 2杨金奎.ADOPT研究的最新结果[J].国际内分泌代谢杂志,2007,27(1):1-3. 被引量:6
  • 3虞爱华.氟哌酸对儿童安全性观察[J].中华儿科杂志,1991,(4):223-224.
  • 4JonesJP.Etiology and pathogenesis of osteonecrosis[J].中华骨科杂志,1994,14(3):153-162.
  • 5Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone mefformin or glyburide monotherapy [J].N Engl J Med, 2006, 355: 2427 - 2443.
  • 6Nathan DM. Thiazolidinediones for initial treatment of type 2 diabetes [ J ]. N Engl J Med, 2006, 355: 2477 - 2480.
  • 7Berger J, Moiler DE. The mechanisms of action of PPARs [ J ]. Annu Rev Med,2002,53:409 - 435.
  • 8Rzonea SO,Suva IJ, Gaddy D, et al. Bone is a target for the antidiabetic compound rosiglitazone[J]. Endocrinology, 2004, 145:401 - 406.
  • 9Khan E, Abu-Amer Y. Activation of peroxisome proliferator-activated receptor-gamma inhibits ditierentiatlon of preostcoblasts [J]. J Lab Clin Med,2003,142:29 -34.
  • 10Soreceanu MA, Miao D, Bai XY, et al. Rosiglitazone impacts negatively on bone by promoting osteoblastf osteocyte apoptosis [J]. J Endocrinol, 2004, 183: 203 - 216.

共引文献2673

同被引文献30

引证文献3

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部